Latest Headlines

31. Bruker Launches MyGenius PRO High-Throughput Sample-To-Answer Molecular Diagnostics System At ESCMID 2026 4/17/2026

    At ESCMID Global 2026, the Bruker Microbiology & Infection Diagnostics division (Bruker Corporation, Nasdaq: BRKR) announces the European launch of MyGenius PRO, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology.

32. QIAGEN To Showcase New Sample To Insight Solutions For Complex Oncology Applications At AACR 2026 4/16/2026

    QIAGEN N.V. today announced it will showcase its oncology workflow applications at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego, demonstrating how its portfolio connects sample preparation with multi-omics profiling and genomic data interpretation to support cancer research and molecular diagnostics.

33. Thermo Fisher Scientific Launches Applied Biosystems™ PowerFlex™ Thermal Cycler To Advance PCR Flexibility Productivity 4/16/2026

    Thermo Fisher Scientific Inc., the world leader in serving science, today announced the Applied Biosystems PowerFlex Thermal Cycler, a next-generation polymerase chain reaction (PCR) instrument designed to help deliver enhanced flexibility, precise thermal performance and improved productivity for modern molecular biology laboratories.

34. Re:Cognition Health Delivers Landmark International Clinical Trial To Explore Whether A Simple Finger-Prick Blood-Based Biomarker Test Can Provide Earlier Alzheimer's Diagnosis 4/15/2026

    Re:Cognition Health, a global leader in new treatments for Alzheimer's Disease, is delivering an international clinical trial to evaluate whether a simple finger-prick blood test can revolutionize how Alzheimer's disease is diagnosed.

35. Cepheid And Oxford Nanopore Expand Partnership Following Successful Phase One Collaboration 4/15/2026

    Cepheid, a Danaher company and a leader in molecular diagnostics for infectious diseases, and Oxford Nanopore Technologies, the company delivering a new generation of nanopore-based molecular sensing technology for real-time genomic analysis, today announced an expansion of their partnership to develop a workflow for rapid bacterial and fungal pathogen identification.

36. Waters Announces CE Mark For Next-Generation Fully Automated BD BACTEC FXI Culture System For Bloodstream Infection Diagnosis 4/15/2026

    Waters Corporation (NYSE: WAT) today announced that the BD BACTEC™ FXI Culture System has received CE marking under the European Union's In Vitro Diagnostic Regulation (IVDR), enabling commercialization in Europe and representing a key milestone in the Company's clinical microbiology portfolio expansion.

37. Invivoscribe Announces The PrepQuant™ System, An Integrated Sample Preparation Platform That Standardizes And Streamlines Pre-Analytical Workflows 4/15/2026

    Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced the launch of the PrepQuant System, a novel sample preparation platform that integrates nucleic acid extraction, concentration, and quantification with a single automated instrument.

38. QIAGEN Expands Into Bloodstream Infection Syndromic Testing With New Rapid QIAstat-Dx Panel 4/14/2026

    QIAGEN N.V. today announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel.

39. Labcorp Introduces AI-Powered Real-World Data Platform With AWS And Datavant To Accelerate Alzheimer's Research 4/14/2026

    Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced a new AI-powered real-world data platform, designed to help researchers and biopharmaceutical companies analyze Alzheimer's disease-related data faster.

40. Biomark Diagnostics To Present Liquid Biopsy Platform At The Canadian Thoracic Society Research Forum 4/14/2026

    BioMark Diagnostics Inc. (“BioMark” or the “Company”) a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that the Company has been selected as one of the top four innovators to present its liquid biopsy platform at the annual Canadian Thoracic Society (CTS) Research Forum.